Ocular Therapeutix (OCUL) Accounts Payables (2013 - 2026)

Ocular Therapeutix's Accounts Payables history runs 14 years deep, the most recent figure standing at $8.0 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 73.5% year-over-year to $8.0 million in Q1 2026; TTM through Mar 2026 was $8.0 million, a 73.5% increase from a year earlier, with the FY2025 full-year figure at $4.2 million, down 0.53% from the prior year.
• Accounts Payables improved to $8.0 million in Q1 2026 per OCUL's latest filing, from $4.2 million in the prior quarter.
• Across five years, Accounts Payables topped out at $8.0 million in Q1 2026 and bottomed at $3.4 million in Q1 2022.
• The 5-year median for Accounts Payables is $4.4 million (2023), against an average of $4.8 million.
• Across the five-year window, Accounts Payables declined 28.31% in 2025 and jumped 73.5% in 2026, its largest moves.
• Year by year, Accounts Payables stood at $5.1 million in 2022, then decreased by 14.33% to $4.4 million in 2023, then declined by 4.85% to $4.2 million in 2024, then retreated by 0.53% to $4.2 million in 2025, then surged by 93.21% to $8.0 million in 2026.
• Per Business Quant, the three latest OCUL Accounts Payables figures stand at $8.0 million (Q1 2026), $4.2 million (Q4 2025), and $6.3 million (Q3 2025).